Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02500121 · ClinicalTrials.gov registry record · Phase 2
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
A Phase 2 study, sponsored by Matthew Galsky.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT02500121 is a Phase 2 study that has completed, run by Matthew Galsky. The registered enrollment target is 108 participants.
The verdict
NCT02500121, a Phase 2 study, has completed, sponsored by Matthew Galsky.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
This is a multi-institutional, randomized, placebo controlled, double-blinded phase II trial of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer who have achieved at least stable disease on first-line chemotherapy.
Interventions
- DRUG Pembrolizumab
- OTHER Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2015-11-11 |
| Est. Completion | 2021-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02500121
The ClinicalTrials.gov registry entry for NCT02500121 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Matthew Galsky, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02500121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02500121 about?
NCT02500121 is a clinical study titled "Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer". This is a multi-institutional, randomized, placebo controlled, double-blinded phase II trial of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer who have achieved at least stable disease on first-line chemotherapy.
What is the current status of trial NCT02500121?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2015-11-11. Estimated completion is 2021-01-01.
What interventions are being tested in trial NCT02500121?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (OTHER).
Who is sponsoring clinical trial NCT02500121?
This trial is sponsored by Matthew Galsky, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.